Disease landscape

Schizophrenia clinical trials

Get alerts when Schizophrenia trials change

480 active trials 280 recruiting 37 Phase 3 274 sponsors 60 changes in 30 days

Data updated daily from ClinicalTrials.gov, last refresh 2026-09-16

What changed in the last 30 days showing 45 of 60 changes on 20 trials

2026-09-11
notable
Primary completion pushed: 2026-12-31 → 2027-03-31
Trial sites expanded: 15 → 19 locations
Completion pushed: 2026-12-31 → 2027-03-31
NCT07184619 Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With… · Newron Pharmaceuticals SPA · Phase 3
2026-09-16
critical
Primary endpoint(s) modified
NCT07145918 A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine… · AbbVie · Phase 2
2026-09-09
critical
Primary completion pushed: 2025-12-31 → 2028-06
Enrollment reopened
Completion pushed: 2025-12-31 → 2028-06
NCT03911726 Do Antipsychotic Agents Induce Supersensitivity in Humans: A Combined PET/MRI Study in… · Central Institute of Mental Health, Mannheim
2026-08-26
critical
Primary completion pushed: 2026-12 → 2027-09-30
Completion pushed: 2026-12 → 2027-12-31
NCT02639702 Switching From Twice-Daily to Once-Daily Clozapine Dosing in Schizophrenia · Centre for Addiction and Mental Health · Phase 4
2026-08-29
critical
Primary completion pushed: 2026-04-30 → 2027-04-30
Completion pushed: 2026-04-30 → 2027-04-30
NCT07192042 Investigation of Using Non-Wearable Devices to Assess Sleep- Disordered Breathing in… · Taipei Medical University Shuang Ho Hospital
2026-08-28
notable
Primary completion pushed: 2026-03-31 → 2026-09
Enrollment closed, study ongoing
Completion pushed: 2026-03-31 → 2026-09
NCT05435300 Does tDCS Change Synaptic Density in the Brains of Patients With Schizophrenia · Centre for Addiction and Mental Health
2026-08-26
critical
Primary completion pushed: 2026-03-31 → 2027-03
Enrollment closed, study ongoing
Completion pushed: 2026-03-31 → 2027-03
NCT04033679 The Effects of Non-invasive Brain Stimulation on Treatment Adherence in Schizophrenia · Centre for Addiction and Mental Health
2026-09-11
critical
Primary endpoint(s) modified
Trial status changed: Recruiting → Not Yet Recruiting
NCT07559084 Multi-target TMS for Schizophrenia Negative Symptoms · Shanghai Mental Health Center
2026-08-28
critical
Enrollment reduced: 26 → 15 participants
Trial completed
Completion moved earlier: 2025-12 → 2025-02-14
NCT05017532 Cognitive Remediation for Social Cognition in Schizophrenia and Related Disorders · Douglas Mental Health University Institute
2026-08-28
critical
Enrollment reduced: 390 → 192 participants
Trial completed
Primary completion moved earlier: 2029-08-31 → 2026-07-31
Completion moved earlier: 2029-08-31 → 2026-07-31
NCT05661448 Promoting Cognitive Health in Schizophrenia · Douglas Mental Health University Institute
2026-08-21
critical
Enrollment reduced: 200 → 135 participants
Trial completed
Primary completion moved earlier: 2025-12-31 → 2025-11-25
Completion moved earlier: 2026-05-31 → 2025-12-16
NCT05929352 Song-making In a Group (SING) · Yale University
2026-09-15
notable
Recruitment opened
NCT07686263 Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia · Karuna Therapeutics, Inc., a Bristol Myers Squibb company · Phase 3
2026-09-12
notable
Trial completed
Final enrollment: 247 participants (planned 190)
NCT05326347 A Long-term Administration Trial of Brexpiprazole Once-weekly (QW) Formulation in… · Otsuka Pharmaceutical Co., Ltd. · Phase 3
2026-09-10
notable
Trial completed
NCT06791122 A Prospective Cohort Study to Assess Clinical Effectiveness of an Investigational Digital… · Boehringer Ingelheim
2026-09-16
notable
Trial status changed: Enrolling by Invitation → Completed
Primary completion confirmed: January 2026 (last estimated June 2026)
NCT07155096 Accelerated DMN-Targeted cTBS to Modulate DMN Connectivity · Vanderbilt University Medical Center
2026-09-03
notable
Recruitment opened
Enrollment increased: 48 → 53 participants
Primary completion moved earlier: 2027-12 → 2027-06
NCT07427810 Follow-up of Adolescents With Autism and Psychotic Symptoms - Psychiatric Co-morbidity… · Värmland County Council, Sweden
2026-08-20
notable
Recruitment opened
NCT06898879 Enhancing Veteran-Clinical Collaboration in VA PRRCs · VA Office of Research and Development
2026-08-18
notable
Enrollment closed, study ongoing
NCT06881810 Enhancing Social Skills in Schizophrenia Spectrum Disorders - Oxytocin as add-on to… · Central Institute of Mental Health, Mannheim · Phase 2
2026-08-25
notable
Completed without a posted recruiting period
Primary completion pushed: 2026-03-31 → 2026-06-15
NCT07374588 Impact of Medication Education on Adherence and Side Effects · Cumhuriyet University
2026-08-22
notable
Recruitment opened
Enrollment increased: 62 → 74 participants
NCT07658898 dACC-Targeted Temporal Interference for Negative and Cognitive Symptoms in Schizophrenia · Shanghai Pudong New Area Mental Health Center, School of Medicine, Tongji University

New sponsor entrants, last 90 days sponsors with their first trial in this area

First postedTrialSponsorPhase
2026-09-14 NCT07818668 tACS for Self-Other Boundary in Schizophrenia Chunyan Zhu new
2026-09-14 NCT07817069 Effects of Nitraria Retusa Infusion on Clozapine-induced Metabolic Side Effects Faculty of Medicine, Sousse new
2026-09-11 NCT07815587 Ultrasound Assessment of Gluteal Muscle in Patients Receiving Depot Antipsychotics and… St. Olavs Hospital new
2026-09-11 NCT07815210 Phase I Trial of HHK101 in Patients With Schizophrenia Zhuhai Huahaikang Pharmaceutical Technology Co., Ltd. new Phase 1
2026-09-03 NCT07802132 A Prospective, Observational, Single-Arm, Multicenter Real-World Study Evaluating the… Zai Lab (Shanghai) Co., Ltd. new
2026-08-24 NCT07781007 Effectiveness of a Board Game Intervention on Cognitive and Functional Outcomes in Older… Kaohsiung Kai-Suan Psychiatric Hospital new
2026-08-19 NCT07773831 Efficacy and Safety of Temporal Interference Stimulation in Treatment-Resistant… Zhimin Wang new
2026-08-12 NCT07759895 Combination Therapy of Deferiprone and N-Acetylcysteine for Treating Negative Symptoms in… Amit Lotan new Phase 2
2026-08-10 NCT07755605 Digital Therapeutics for Social Cognitive Function in Schizophrenia Spectrum Disorder Samsung Medical Center new
2026-08-05 NCT07748078 Snoezelen Therapy in Adults With Alcohol Dependence and Adults With Schizophrenia The Jerzy Kukuczka Academy of Physical Education in Katowice new

Active trials by phase

Early Phase 1
4
Phase 1
19
Phase 1/2
11
Phase 2
36
Phase 2/3
4
Phase 3
33
Phase 4
24
Not charted: 349 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Active trials top 25 of 480

NCT IDTitleSponsorStatusUpdated
Phase 4
NCT02639702 Switching From Twice-Daily to Once-Daily Clozapine Dosing in Schizophrenia Centre for Addiction and Mental Health Recruiting 2026-08-25
NCT06969755 Biomarkers to Enhance Early Schizophrenia Treatment Northwell Health Recruiting 2026-07-31
NCT06740890 Exercise and Olanzapine-samidorphan New York State Psychiatric Institute Recruiting 2026-07-13
NCT06562608 Anticholinergic Deprescription in Schizophrenia Deepak K. Sarpal, M.D. Recruiting 2026-07-10
NCT07105111 A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive… Neurocrine Biosciences Recruiting 2026-06-16
NCT04113993 Bazedoxifene -Treatment for Women With Schizophrenia The Alfred Recruiting 2026-06-03
NCT05823532 Anti-Inflammatory Challenge in Schizophrenia Emory University Recruiting 2026-06-03
NCT07221877 A Study to Evaluate the Effect of KarXT on Urological Safety Bristol-Myers Squibb Recruiting 2026-06-03
NCT06174116 Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With… University of Massachusetts, Worcester Recruiting 2026-05-22
NCT04580134 CLOZAPINE Response in Biotype-1 University of Texas Southwestern Medical Center Recruiting 2026-05-11
NCT05208190 Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial New York State Psychiatric Institute Recruiting 2026-05-04
NCT04478838 "Extended" (Alternate Day) Antipsychotic Dosing Centre for Addiction and Mental Health Recruiting 2026-04-13
NCT05316883 Biomarkers in Clozapine-responding Schizophrenia Jimmi Nielsen Recruiting 2026-01-20
NCT05958875 The Effect of a Six Week Intensified Pharmacological Treatment for Schizophrenia Compared… Dr. Inge Winter Recruiting 2025-09-26
NCT05648591 Safety and Tolerability of Open-Labeled Iloperidone in Adolescents Vanda Pharmaceuticals Recruiting 2025-03-04
NCT03495024 Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological… Corporal Michael J. Crescenz VA Medical Center Recruiting 2019-03-22
NCT07615075 Clinical Trial of an IL-23 Inhibitor for Immune Activation in Clinical Trial of an IL-23… University of Maryland, Baltimore Not Yet Recruiting 2026-05-29
NCT07047651 Τhe Combination of Pharmacotherapy With RECOVERYTRSGR and RECOVERYTRSBDGR. Dr. Stavroula Rakitzi Active, Not Recruiting 2026-05-01
NCT07075237 Efficacy and Functional Recovery After Switching From Paliperidone Palmitate Injection to… Jiangsu Province Nanjing Brain Hospital Not Yet Recruiting 2025-09-29
NCT03575000 Bromocriptine for Patients With Schizophrenia and Prediabetes VA Pittsburgh Healthcare System Not Yet Recruiting 2025-09-22
NCT07153835 Efficacy and Safety of Paliperidone in Schizophrenia - Bangladesh Study Sher-E-Bangla Medical College Not Yet Recruiting 2025-09-04
NCT06923891 An Open-Label Study to Evaluate the Efficacy and Tolerability of Xanomeline/Trospium In… Vanguard Research Group Not Yet Recruiting 2025-04-11
NCT06924255 An 8-week Open-label Study of an Accelerated and Slower Switching to Xanomeline/Trospium… Collaborative Neuroscience Research, LLC Not Yet Recruiting 2025-04-11
NCT04892199 Does GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic… Anders Fink-Jensen, MD, DMSci Active, Not Recruiting 2024-09-25
Phase 3
NCT07686263 Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia Karuna Therapeutics, Inc., a Bristol Myers Squibb company Recruiting 2026-09-14

Top sponsors by active trials in this area

Get alerts when Schizophrenia trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.
Start monitoring free